ASH 2022 | EMN19 trial update: DaraVCD for multiple myeloma with extramedullary disease
Meral Beksac, MD, Ankara University, Ankara, Turkey, discusses the results of the Phase II EMN19 trial (NCT04166565), which is evaluating daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (DaraVCD) for the treatment of patients with multiple myeloma (MM) with extramedullary disease (EMD). The trial reported a benefit with DaraVCD with respect to overall response rate (ORR). Dr Beksac also highlights factors that had an impact on patient response in this trial, namely plasmacytoma number. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
